J Korean Med Sci.  2024 Feb;39(5):e45. 10.3346/jkms.2024.39.e45.

Establishment of Safety Monitoring System for Vaccines Not Included in the National Immunization Program in Korea

• Nham E
• Yoon JG
• Choi MJ
• Seo YB
• Lee J
• Choi WS
• Hyun H
• Seong H
• Noh JY
• Song JY
• Kim WJ
• Cheong HJ

• KMID: 2551976
• DOI: http://doi.org/10.3346/jkms.2024.39.e45

Abstract

Background
In Korea, there are no surveillance programs for vaccines that are not included in the national immunization program (NIP), and vaccine safety monitoring in the adult population is inadequate. This study aimed to establish a safety monitoring system for nonNIP vaccines in adults.
Methods
Frequently administered non-NIP vaccines were selected. Individuals were included if they received at least one of the selected vaccines at a participating institution and provided informed consent. Solicited and unsolicited adverse events were monitored using questionnaires sent through text messages on days 1, 3, 7, 28, and 90 post-vaccination. Selected adverse events of special interest (AESIs) were monitored monthly by retrospective review of electronic medical records. Causality was assessed according to the Korea Disease Control and Prevention Agency guidelines.
Results
Four vaccines (tetanus-diphtheria-pertussis [Tdap], pneumococcal conjugate 13-valent [PCV13], live zoster vaccine [ZVL], and recombinant zoster vaccine [RZV]) were selected, and their safety profiles were monitored at four tertiary hospitals and 10 primary care clinics. The response rates of the questionnaires on post-vaccination days 1, 7, 28, and 90 were 99.2%, 93.6%, 81.0%, and 48.7%, respectively. Of 555 AESI identified over 10 months, 10 cases received one of the selected non-NIP vaccines within 90 days of the event.
Conclusion
We are establishing the first safety monitoring system for selected non-NIP vaccines in Korea since September 2022 and report its progress as of July 2023. However, continuous government support is essential for its maintenance and improvement.

Keyword

Vaccines; Safety; Monitoring; Surveillance; Non-NIP

Reference

1. Korea Disease Control and Prevention Agency. National Immunization Program for children. Updated 2023. Accessed July 17, 2023. https://www.kdca.go.kr/contents.es?mid=a30333000000 .

2. Yun JW, Noh JY, Song JY, Chun C, Kim Y, Cheong HJ. The Korean influenza national immunization program: history and present status. Infect Chemother. 2017; 49(4):247–254. PMID: 29299891.

3. Korea Disease Control and Prevention Agency. Planning and implementation of elderly immunization program against invasive pneumococcal disease in Korea. Updated 2013. Accessed July 17, 2023. https://www.kdca.go.kr/filepath/boardDownload.es?bid=0034&list_no=21407&seq=1 .

4. World Health Organization. Ten threats to global health in 2019. Updated 2023. Accessed July 17, 2023. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019 .

5. Nham E, Kim YE, Jung J, Kim DW, Jang H, Hyun H, et al. COVID-19 vaccination rates in patients with chronic medical conditions: a nationwide cross-sectional study. J Korean Med Sci. 2022; 37(45):e325. PMID: 36413798.

6. Wie SH, Jung J, Kim WJ. Effective vaccination and education strategies for emerging infectious diseases such as COVID-19. J Korean Med Sci. 2023; 38(44):e371. PMID: 37967881.

7. Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015; 33(36):4398–4405. PMID: 26209838.

8. Baggs J, Gee J, Lewis E, Fowler G, Benson P, Lieu T, et al. The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics. 2011; 127(Suppl 1):S45–S53. PMID: 21502240.

9. Baker MA, Nguyen M, Cole DV, Lee GM, Lieu TA. Post-licensure rapid immunization safety monitoring program (PRISM) data characterization. Vaccine. 2013; 31(Suppl 10):K98–112. PMID: 24331080.

10. Canadian Adverse Events Following Immunization Surveillance System (CAEFISS). Adverse events following immunization in Canada. Updated 2023. Accessed July 17, 2023. https://www.canada.ca/en/public-health/services/immunization/canadian-adverse-events-following-immunization-surveillance-system-caefiss.html#_About_the_system .

11. Bettinger JA, Halperin SA, Vaudry W, Law BJ, Scheifele DW. Canadian IMPACT members. The Canadian Immunization Monitoring Program, ACTive (IMPACT): active surveillance for vaccine adverse events and vaccine-preventable diseases. Can Commun Dis Rep. 2014; 40(Suppl 3):41–44. PMID: 29769912.

12. Pillsbury A, Quinn H, Cashman P, Leeb A, Macartney K. AusVaxSafety consortium. Active SMS-based influenza vaccine safety surveillance in Australian children. Vaccine. 2017; 35(51):7101–7106. PMID: 29128379.

13. Korea Disease Control and Prevention Agency. Adverse event reporting system. Updated 2023. Accessed July 17, 2023. https://nip.kdca.go.kr/irhp/infm/goVcntInfo.do?menuLv=1&menuCd=1522 .

14. Ministry of Food and Drug Safety. Republic of Korea Implementation Guide: Electronic Transmission of Individual Case Safety Reports E2B (R3) Data Elements and Message Specification. Updated 2019. Accessed July 17, 2023. https://www.mfds.go.kr/brd/m_1060/view.do?seq=14313 .

15. Nham E, Song JY, Noh JY, Cheong HJ, Kim WJ. COVID-19 vaccination in Korea: past, present, and the way forward. J Korean Med Sci. 2022; 37(47):e351. PMID: 36472087.

16. Korea Disease Control and Prevention Agency. Management of adverse events after COVID-19 vaccination. Updated 2022. Accessed July 18, 2023. https://ncv.kdca.go.kr/board.es?mid=a12101000000&bid=0031#content .

17. Chang S, O’Connor PM, Slade BA, Woo EJ. U.S. Postlicensure safety surveillance for adolescent and adult tetanus, diphtheria and acellular pertussis vaccines: 2005-2007. Vaccine. 2013; 31(10):1447–1452. PMID: 23142308.

18. Kovac M, Kostanyan L, Mesaros N, Kuriyakose S, Varman M. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: an open, phase III, non-randomized, multi-center study. Hum Vaccin Immunother. 2018; 14(8):1977–1986. PMID: 29630439.

19. Haber P, Moro PL, Ng C, Dores GM, Perez-Vilar S, Marquez PL, et al. Safety review of tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccines (Tdap) in adults aged ≥65 years, Vaccine Adverse Event reporting System (VAERS), United States, September 2010-December 2018. Vaccine. 2020; 38(6):1476–1480. PMID: 31883809.

20. Munoz FM, Bond NH, Maccato M, Pinell P, Hammill HA, Swamy GK, et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA. 2014; 311(17):1760–1769. PMID: 24794369.

21. Destefano F, Pfeifer D, Nohynek H. Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure data. Bull World Health Organ. 2008; 86(5):373–380. PMID: 18545740.

22. Isturiz RE, Hall-Murray C, McLaughlin JM, Snow V, Schmoele-Thoma B, Webber C, et al. Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age. Expert Rev Vaccines. 2018; 17(1):45–55. PMID: 29183235.

23. Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012; 54(7):922–928. PMID: 22291101.

24. Vesikari T, Hardt R, Rümke HC, Icardi G, Montero J, Thomas S, et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules. Hum Vaccin Immunother. 2013; 9(4):858–864. PMID: 23319176.

25. Strezova A, Lal H, Enweonye I, Campora L, Beukelaers P, Segall N, et al. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged ≥50 years: a randomized trial. Vaccine. 2019; 37(39):5877–5885. PMID: 31443993.

26. Racine É, Gilca V, Amini R, Tunis M, Ismail S, Sauvageau C. A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18-49 year old patients. Vaccine. 2020; 38(40):6205–6214. PMID: 32788132.

27. Fiore J, Co-van der Mee MM, Maldonado A, Glasser L, Watson P. Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance. Ther Adv Vaccines Immunother. 2021; 9:25151355211057479. PMID: 35005428.